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Supplementary methods
DNA preparation
For frozen samples, genomic DNA was extracted with a DNeasy Blood and Tissue Mini Kit (Qiagen) . For FFPE samples, genomic DNA was extracted with a QIAamp DNA FFPE Tissue Kit (Qiagen), according to the manufacturer's instructions.
Western blot
Cells were lysed in 200µl of lysis buffer (0.5M Tris-HCl, pH 6.8, 2mM EDTA, 10% glycerol, 2% SDS and 5% β-mercaptoethanol). Protein extracts (20µg) were electrophoresed on 10% SDS polyacrylamide gels and transferred to nitrocellulose membranes. Membranes were blocked with 5% nonfat dried milk in Tris-buffered saline (CWBIO, CW0042) and incubated for 2h at room temperature with the appropriate primary antibody, followed by a horseradish peroxidase-conjugated secondary antibody. The immunocomplexes were visualized using a chemiluminescence phototope-horseradish peroxidase kit (Cell Signaling Technologies, 7003) .
Anti-H3K4me1 (61633) and anti-H3K4me2 (39913) were from Active Motif. Anti-H3K4me3 (ab8580) and anti-H3K18Ac (ab1191) antibody were from Abcam. Horseradish 4 peroxidase-conjugated goat anti-mouse IgG (sc-2005) and goat anti-rabbit IgG (sc-2004) antibodies were from Santa Cruz Biotechnology. Histone (H3) (Proteintech, 17168-1-AP) was used to monitor equivalent protein loading.
Immunofluorescence and immunohistochemistry
Immunofluorescence assay was performed on acetone-fixed cells using an anti-H3K4me3 (Abcam, ab8580) antibody and an Alexa Fluor 488-conjugated goat anti-rabbit IgG (H+L) (ThermoFisher, A-11034) secondary antibody. Nuclei were counterstained with DAPI.
Immunohistochemistry was performed on 5µm-paraffin sections with an indirect immunoperoxidase method using antibodies against H3K4me3 (Abcam, ab8580), H3K18ac (Abcam, ab1191) and p-ERK (Cell Signaling Technologies, 4370). Expression levels were scored semi-quantitatively based on the percentage of positive cells: +, <25%; ++, 25-49%; +++, 50-74%; ++++, 75-100%.
Isobolographic analysis
To determine the synergistic effect of chidamide combined with decitabine, the combination index (CI) method described by Chou 1 and Talalay and the Calcusyn software program (Biosoft, 5 Cambridge, UK) for automated analysis were performed. This method allows quantitative determination of drug interactions, where CI<1, =1, and >1 indicate synergism, additive effect, and antagonism, respectively. When the drugs were combined, the CI values were calculated for each experiment and for combination experiment at a fixed concentration ratio. When at least 80% of CI values for a combination were <1, the drug combination was considered to be synergistic.
mRNA-seq library preparation and sequencing analysis
Total RNA (1µg) was purified using Ribo-Zero rRNA Removal Kits (Illumina). RNA size, concentration, and integrity were verified using Agilent 2100 Bioanalyzer (Agilent). RNA libraries were constructed by using rRNA-depleted RNAs with TruSeq Stranded Total RNA Library Prep Kit (Illumina) according to the manufacturer's instructions. Libraries were controlled for quality and quantified using BioAnalyzer 2100 system (Agilent). 10pM libraries were denatured as single-stranded DNA molecules, captured on Illumina flow cells, amplified in situ as clusters and finally sequenced for 150 cycles on Illumina HiSeq Sequencer. Paired-end reads were harvested from Illumina HiSeq Sequencer, and were quality controlled by Q30. After 3' adaptor-trimming and low quality reads removing by cutadapt software (v1.9), the high quality trimmed reads were aligned to the reference genome (UCSC hg19) guided by the Ensembl GFF 6 gene annotation file with hisat2 software (v2.0.4). Then, cuffdiff software (part of cufflinks) was used to get the gene level FPKM as the expression profiles of mRNA, and fold change and p-value were calculated based on FPKM, differentially expressed mRNA were identified. Pathway enrichment and GSEA analysis were performed based on the differentially expressed mRNAs.
The data is available on NCBI (Accession number GSE104280).
ChIP-seq library preparation and sequencing analysis
Chromatin immunoprecipitation was performed according to Wamstad et al 2 . The yield of ChIPed DNA was determined via Quant IT fluorescence assay (Life Technologies) and enrichment efficiencies of ChIP reactions were evaluated by qPCR. Illumina sequencing libraries were generated with NEBNext® Ultra™ DNA Library Prep Kit (New England Biolabs) following the manufacturer's manual. The library quality was determined by Agilent 2100 Bioanalyzer (Agilent), and subjected to high-throughput 150bp paired-end sequencing on Illumina Hiseq sequencer according to the manufacturer's protocol. Q30 was used to perform quality control on the raw sequencing data. Adaptor-trimming and low quality reads were removed by cutadapt (v1.9.1) software. High quality reads were aligned to human genome (UCSC hg19) using bowtie2 7 software (v2.2.4) with default parameters. Peak calling was performed with MACS software (v1.4.3). Differentially enriched regions were identified by diffReps software (v1.55.4). The enriched peaks were annotated with the latest UCSC RefSeq database to connect the peak information with the gene annotation. KEGG Pathway analysis was performed on the peak-associated genes or differentially enriched peak-associated genes. Enriched peaks were visualized on UCSC Genome Browser. The data is available on NCBI (Accession number GSE104289).
TUNEL assay
TUNEL assay was performed by in situ cell death detection kit (Roche) and detected DNA fragmentation by fluorescence microscopy.
Murine model
Nude mice (4 to 5 weeks old, Shanghai Laboratory Animal Center, Shanghai, China) were injected subcutaneously with 4×10 7 KMT2D-mutated (V5486M) Jurkat cells into the right flank.
Treatments (10 mice per group) were started after the tumor became about 0.5×0.5cm in surface (day 0). The untreated group received RPMI1640, whereas the other three groups received twice 8 weekly for three weeks of chidamide (12.5 mg/kg) and/or decitabine (0.5 mg/kg), respectively.
Tumor volumes were calculated as 0.5×a(length)×b(width) 2 . Animals were used according to the protocols approved by the Shanghai Rui Jin Hospital Animal Care and Use Committee.
Micro-PET-CT imaging
Mice were subjected to positron emission tomography-computed tomography (PET-CT) analysis after 21 days of treatment. PET-CT imaging was performed on an Inveon MM Platform (Siemens Preclinical Solutions) with 8.5cm transaxial and 5.7cm axial fields of view.
18F-fluorodeoxyglucose (0.1ml per injection with an activity of 10MBq) was injected to anesthetized mice through the tail vein. Mice were placed prone on the PET scanner bed 45 min later near the central field of view for scanning process in Inveon Acquisition Workplace 1.5.0.28.
Ten-minute CT X-ray for attenuation correction was scanned with a power of 80kV and 500µA and an exposure time of 1100 ms before PET scan. Ten-minute static PET scans were then acquired, and images were reconstructed by an OSEM3D (three-dimensional ordered subsets expectation maximum) algorithm followed by MAP (maximization/maximum a posteriori) or FastMAP provided by Inveon Acquisition Workplace. The three-dimensional regions of interest were drawn over the heart guided by CT images and tracer uptake was measured using the 9 software of Inveon Research Workplace (IRW) 3.0. Individual quantification of the 18F-fluorodeoxyglucose uptake in each of them was calculated. Mean standardized uptake values were determined by dividing the relevant regions of interest concentration by the ratio of the injected activity to the body weight. EZH2 0/73 (0%) 0/26 (0%) 0/26 (0%) P value 1 indicated difference between training cohort and validation cohort. P value 2 indicated difference between arm A and arm B within validation cohort.
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